“Many investors, especially more aggressive traders, look at lower-priced stocks as a way to not only make some good money but to get a higher share count,” notes the author of today’s article. He proceeds to highlight five low-priced biotech and medtech stocks with significant upside potential to consider for very aggressive accounts. For these five stocks – including a clinical-stage biopharmaceutical company working on a potential blockbuster treatment for post-traumatic stress disorder – CLICK HERE.
5 Low-Priced, Big-Upside Biotech And Medtech Stocks “For Very Aggressive Accounts”
Tags:Aggressive AccountsAggressive TradersBiopharmaceutical InvestmentsClinical Stage BiopharmaceuticalsInvestinginvestorinvestorsLow-Priced Biotech StocksMedtech StocksmoneyShare CountsSharesStock Marketstocks